Cost-Benefit Evaluation Of A New Technology For Treatment Of Peptic-Ulcer Disease
MANAGERIAL AND DECISION ECONOMICS(1983)
摘要
AbstractPsychosocial benefit resists monetary expression. However, reduction in costs, with no loss of benefits assumed, improves a cost‐benefit ratio. The effect of cimetidine on the costs of ulcer has been widely studied. Randomized clinical trials show reductions in surgery and work loss among cimetidine‐treated patients versus placebo controls. In the community, time series studies have documented drops in ulcer surgery, averaging about 25% below the expected trend line, following marketing introduction of the drug. These, plus a cross‐sectional study of Medicaid patients with and without use of cimetidine, indicate that the drug has reduced the net direct costs of ulcer disease.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要